Glycaemic and Insulinaemic Responses After Consumption of FOS. (GLYCOFOS-cake)

January 28, 2015 updated by: Jean-Michel Lecerf, Institut Pasteur de Lille

Postprandial Glycaemic and Insulinaemic Responses After Consumption of Minicakes Containing FOS in Adults

The study aims to evaluate the glycaemic and insulinaemic response of short-chain fructo-oligosaccharides (scFOS) used to replace sugars (e.g. dextrose) in foods.

Study Overview

Status

Completed

Conditions

Intervention / Treatment

Study Type

Interventional

Enrollment (Actual)

50

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

    • Nord
      • Lille, Nord, France, 59019
        • NutrInvest - Institut Pasteur de Lille

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years to 50 years (Adult)

Accepts Healthy Volunteers

Yes

Genders Eligible for Study

All

Description

Inclusion Criteria:

  • Body mass index (BMI) between 18.0 and 25.0 kg/m² (included);
  • Ready to keep the same volume of physical activity and the same dietary habits during the study and particularly 24 hours before each visit;
  • Be used to have breakfast;
  • Non-smoker for at least 3 months;
  • For the female participant: not being pregnant or breastfeeding and using efficient birth control;
  • Signed the consent form;
  • Able to follow the instructions of the study;
  • Health insured;
  • Accepted to be included in the National Registry for biomedical research Volunteers (Fichier VRB, Volontaires Recherches Biomédicales).

Exclusion Criteria:

  • Fasting blood glucose over 6.1 mmol/L (1.10 g/L) (or diabetes treated or not);
  • Fasting blood cholesterol over 6.35 mmol/L;
  • Fasting blood triglycerides over 1.70 mmol/L (or history of insulinoma);
  • Fasting blood insulin under 20 mU/L;
  • Fasting HbA1c under 7%;
  • History of hypercholesterolemia, hypertension, diabetes or glucose intolerance treated or not;
  • History of dietary allergies or coeliac disease;
  • History of digestive system disease susceptible to modify digestion or absorption like Crohn's disease;
  • Somatic or psychiatric disorders;
  • Renal insufficiency (kidney failure);
  • SGOT or ALAT over 52.5 U/L;
  • Smoker;
  • Consuming more than 3 alcoholic beverage a day;
  • Weight varied 3 kg the last 3 months.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Allocation: Randomized
  • Interventional Model: Crossover Assignment
  • Masking: Quadruple

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Placebo Comparator: Sugar
Control group consuming sponge cakes containing in total 24g of dextrose.
100g of sponge cakes made with 24g of dextrose.
Experimental: FOS
Group consuming sponge cakes in which 30% of the dextrose was replaced by FOS.
100g of sponge cakes made with 19.4g of dextrose and 9.1g of FOS.

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Glycaemic response
Time Frame: 2 hours and 5 minutes
Blood glucose kinetics with 7 points. Analysis of the Area under the curve of glucose.
2 hours and 5 minutes

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Insulinaemic response
Time Frame: 2 hours and 5 minutes
Blood insulin kinetics with 7 points. Analysis of the Area under the curve of insulin.
2 hours and 5 minutes
Blood glucose peak (Cmax)
Time Frame: One-time data (the highest one) within the 2hrs 5mins kinetics.
Peak of blood glucose during kinetics.
One-time data (the highest one) within the 2hrs 5mins kinetics.
Blood insulin peak (Cmax)
Time Frame: One-time data (the highest one) within the 2hrs 5mins kinetics.
Peak of blood insulin during kinetics.
One-time data (the highest one) within the 2hrs 5mins kinetics.
Glucose Tmax : time to reach the peak of blood glucose
Time Frame: One time within the 2hrs 5mins kinetics.
One time within the 2hrs 5mins kinetics.
Insulin Tmax : time to reach the peak of blood insulin
Time Frame: One time within the 2hrs 5mins kinetics.
One time within the 2hrs 5mins kinetics.

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Collaborators

Investigators

  • Principal Investigator: Jean-Michel LECERF, MD, Institut Pasteur de Lille

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start

October 1, 2013

Primary Completion (Actual)

February 1, 2014

Study Completion (Actual)

February 1, 2014

Study Registration Dates

First Submitted

November 25, 2013

First Submitted That Met QC Criteria

January 28, 2015

First Posted (Estimate)

February 2, 2015

Study Record Updates

Last Update Posted (Estimate)

February 2, 2015

Last Update Submitted That Met QC Criteria

January 28, 2015

Last Verified

January 1, 2015

More Information

Terms related to this study

Other Study ID Numbers

  • 2013-A00785-40

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Glycaemia

Clinical Trials on Sugar

3
Subscribe